Search
Contact
04.12.2024 | Deal Notifications

KPMG Law and KPMG advises Brain Biotech AG on license agreements and monetization of license rights

KPMG Law Rechtsanwaltsgesellschaft mbH and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) advised Brain Biotech AG on the monetization of licensing rights with Royalty Pharma and the conclusion of an exclusive pharmaceutical licensing agreement for the G-dase-E®-CRISPR-Cas technology with Akribion Therapeutics.

BRAIN Biotech has entered into an agreement with Royalty Pharma for the monetization of the license rights to the investigational pharmaceutical compound deucrictibant in the amount of up to EUR 128.88 million. BRAIN Biotech will receive an upfront payment of EUR 18.41 million, additional potential regulatory milestone payments of up to EUR 18.42 million and additional potential long-term sales-related milestones of up to EUR 92.05 million. In addition, BRAIN Biotech has entered into an exclusive technology license agreement with Akribion Therapeutics GmbH for the use of the genome editing nuclease G-dase E® for the pharmaceutical sector. BRAIN Biotech will receive up to EUR 92.3 million in R&D and commercial milestone payments from Akribion for the granting of these exclusive rights for use in the pharmaceutical field. In addition, BRAIN Biotech will be entitled to royalties from future net sales. The payment structure is based on progress in clinical development and future commercialization success. KPMG Law provided comprehensive legal advice on the structuring of the transaction, including all aspects of copyright, licensing and transaction law. The accounting and tax advice as well as the comprehensive valuation of the licenses was provided by a KPMG team. Royalty Pharma was advised by an international team from Goodwin Procter. Advisor Brain Biotech AG:

KPMG Law Rechtsanwaltsgesellschaft mbH: Stefan Kimmel (Partner, Corporate/M&A, Berlin), Dr. Anna Wipper (Partner, IP/IT, Berlin) – both lead – Gunars Urdze (Senior Manager, Corporate, M&A, Cologne), Dr. Thomas Beyer (Senior Manager, IP/IT, Berlin), Isabelle Knoché (Senior Manager, Legal Financial Services, Frankfurt/Main), Christina Laux (Senior Associate , Legal Financial Services, Frankfurt/Main),; Dr. Jonas Brueckner (Partner, Antitrust and Foreign Trade Law, Berlin).

KPMG AG Wirtschaftsprüfungsgesellschaft: Christian Klingbeil (Partner, Valuation, Head of Deal Advisory Life Science, Munich), Sebastian Bongartz (Senior Manager, International Transaction Tax, Düsseldorf).

 

Explore #more

09.07.2025 | KPMG Law Insights

Restructuring with staff reductions: preparation is key

The downsizing or closure of a part of a company often also necessitates staff reductions. Depending on the number of employees affected, the works council…

08.07.2025 | Deal Notifications

KPMG Law advises Finish Finnfoam Group on the acquisition of the Phonotherm business of insolvent BOSIG Baukunststoffe GmbH

KPMG Law advised Finnfoam Group (Salo/Finland) on the acquisition of the business unit “Phonotherm” from BOSIG Baukunststoffe GmbH via the newly founded Warmotech GmbH as…

07.07.2025 | Deal Notifications

KPMG Law advises HEMRO International AG on the acquisition of Xenia Espresso GmbH

KPMG Law Rechtsanwaltsgesellschaft mbH (KPMG Law) provided legal advice to HEMRO Group, a global manufacturer of coffee grinders and grinding technologies headquartered in Zurich, Switzerland,…

04.07.2025 | KPMG Law Insights

BGH clarifies the limits of the definition of customer installations

On July 3, 2025, the BGH published the reasons for its ruling of May 13, 2025 (case no. EnVR 83/20) and provided the eagerly awaited…

02.07.2025 | In the media

Guest article by Moritz Püstow on the special fund for infrastructure

The German government wants to invest 500 billion euros in infrastructure and climate neutrality. This creates new business opportunities for the construction industry – but…

01.07.2025 | Deal Notifications

KPMG Law advised Bosch on the multinational carve-out of the entire product business of Bosch Building Technologies to investor Triton

KPMG Law advises Robert Bosch on the carve-out of the building technologies division’s product business for security and communications technology (Bosch Building Technologies) in more…

27.06.2025 | KPMG Law Insights

Hospital restructuring: three steps out of the crisis

Many clinics see their existence threatened in the short or medium term. Other healthcare facilities are also experiencing economic difficulties. Inadequate remuneration structures, staff shortages,…

27.06.2025 | In the media

KPMG Law nominated at the PMN Awards

We are delighted to have been nominated directly in two categories at the PMN Awards 2025. Our “Extended Workbench” project was nominated in the…

25.06.2025 | KPMG Law Insights

Business Travel and Assignment in the USA: What you need to know about US immigration

The recent changes in US immigration rules are causing uncertainty worldwide. In particular, since the new US government took office, processes regarding entry into the…

11.06.2025 | KPMG Law Insights

Omnibus IV brings some simplifications, especially in product law

The EU Commission proposed the fourth omnibus package on May 21, 2025. Omnibus IV contains simplifications in relation to numerous product law requirements and…

© 2024 KPMG Law Rechtsanwaltsgesellschaft mbH, associated with KPMG AG Wirtschaftsprüfungsgesellschaft, a public limited company under German law and a member of the global KPMG organisation of independent member firms affiliated with KPMG International Limited, a Private English Company Limited by Guarantee. All rights reserved. For more details on the structure of KPMG’s global organisation, please visit https://home.kpmg/governance.

 KPMG International does not provide services to clients. No member firm is authorised to bind or contract KPMG International or any other member firm to any third party, just as KPMG International is not authorised to bind or contract any other member firm.

Scroll